Crossmark

Omalizumab Treatment in Uncontrolled Asthma and CRSwNP Patients, with Previous Endoscopic Sinus Surgery, to Improve Quality of Life and Endoscopic Outcomes: a Two-Year Real-Life Study

Crossref DOI link: https://doi.org/10.1007/s11882-023-01106-w

Published Online: 2023-08-30

Published Print: 2023-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Maza-Solano, Juan

Callejon-Leblic, Amparo

Martin-Jimenez, Daniel

Moreno-Luna, Ramon

Gonzalez-Garcia, Jaime

Cuvillo, Alfonso

Sanchez-Gomez, Serafin
License Information

Text and Data Mining valid from 2023-08-30

Version of Record valid from 2023-08-30
More Information

Article History

Accepted: 16 August 2023

First Online: 30 August 2023

Compliance with Ethical Standards

:

: JMS has received honoraria for consultancy, projects, advisory boards and talks from AstraZeneca, GlaxoSmithKline, MSD, Novartis and Sanofi. ACL has no conflicts of interest regarding specific financial interests relevant to this manuscript. DMJ has no conflicts of interest regarding specific financial interests relevant to this manuscript. RML has received fees from GlaxoSmithKline and Sanofi for talks at scientific events and as member of advisory boards. JGG has received lecture fees from GlaxoSmithKline and Sanofi. AC has received honoraria from AstraZeneca, GlaxoSmithKline, MSD, Novartis, Teva and Sanofi for talks at scientific events and as member of advisory boards. SSG has received honoraria for projects, advisory boards and talks from GlaxoSmithKline and Sanofi.

: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of an independent Ethics Committee (FIS-OMA-2022-01). Statements on consent to participate and consent to publish are not applicable.

Document is current

Any future updates will be listed below